What one share of Transcode Therapeutics holds
TransCode is a clinical-stage company pioneering immuno-oncology and RNA therapeutics for treatment of high risk and advanced cancers. Our lead therapeutic product candidate is TTX-MC138, an antisense inhibitor of an oncogenic microRNA.
Transcode Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$51.19 |
|---|---|
| Cash and investments | $8.29 |
| Book value | −$27.38 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2024 | — | −$1,337 | $1.73 | −$1,064 | — | — |
| 2025 | — | −$52.59 | $0.01 | −$28.31 | — | $11.27 |
Common questions about Transcode Therapeutics
How much does one share of Transcode Therapeutics earn?
Over the last 12 months, Transcode Therapeutics lost $51.19 for each share.
Does Transcode Therapeutics pay a dividend?
Transcode Therapeutics didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Transcode Therapeutics’s book value per share?
Transcode Therapeutics’s book value is negative (−$27.38 per share): it owes more than everything it owns is recorded at, often after years of buying back its own shares, as of June 30, 2026.
How much cash and debt does each share of Transcode Therapeutics have?
Each share of Transcode Therapeutics has $8.29 of cash and investments, as of June 30, 2026.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.